Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00808639 · ClinicalTrials.gov registry record · Phase 2
Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma
A Phase 2 study of Bladder Cancer and Muscle-invasive Bladder Cancer, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
- 4
- Study locations
NCT00808639: Completed Phase 2 study of Bladder Cancer and Muscle-invasive Bladder Cancer, sponsored by Dana-Farber Cancer Institute.
NCT00808639 is a Phase 2 study of Bladder Cancer and Muscle-invasive Bladder Cancer that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 39 participants, below the 12,753-participant average among 175 other Bladder Cancer trials with a reported enrollment target (100% lower). The trial reports 4 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00808639, a Phase 2 study of Bladder Cancer and Muscle-invasive Bladder Cancer, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this research study is to test the effectiveness of neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) in combination with pegfilgrastim followed by radical surgery in patients with muscle-invasive urothelial carcinoma.
Primary Outcome
Pathological response is defined as down-staging to \</=pT1, N0 after chemotherapy with pegfilgrastim support.
Conditions Studied
Interventions
- DRUG Doxorubicin
- DRUG Methotrexate
- DRUG cisplatin
- DRUG Pegfilgrastim
- DRUG vinblastine
Study Locations (4)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
- Dana-Farber Cancer Institute - Boston
- Lahey Clinic - Burlington
Pennsylvania
- University of Pittsburgh Cancer Institute - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2008-12 |
| Est. Completion | 2016-09 |
| Phase | Phase 2 |
What the finished NCT00808639 record still lists
NCT00808639 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 12,753-participant average among 175 other Bladder Cancer trials with a reported enrollment target (100% lower).
The record links to 2 conditions, with Bladder Cancer appearing as the primary indexed condition, and to 5 interventions - of which Doxorubicin is the first listed.
NCT00808639 reports a single indexed study location in Massachusetts, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00808639 about?
NCT00808639 is a clinical study titled "Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma". The purpose of this research study is to test the effectiveness of neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) in combination with pegfilgrastim followed by radical surgery in patients with muscle-invasive urothelial carcinoma.
What is the current status of trial NCT00808639?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2008-12. Estimated completion is 2016-09.
What conditions does trial NCT00808639 study?
This clinical trial studies the following conditions: Bladder Cancer, Muscle-invasive Bladder Cancer.
What interventions are being tested in trial NCT00808639?
The interventions under investigation include: Doxorubicin (DRUG), Methotrexate (DRUG), cisplatin (DRUG), Pegfilgrastim (DRUG), vinblastine (DRUG).
Who is sponsoring clinical trial NCT00808639?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00808639 being conducted?
This trial has 4 study locations across Massachusetts, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00808639's enrollment target sits among peer trials
39 128th of 175 higher than 48 of 175 other Bladder Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Bladder Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Telehealth Intervention for Ostomy Self-Management
RECRUITING · Phase 2
-
Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery
RECRUITING · Phase 2
-
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
RECRUITING · Phase 2
-
Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT)
RECRUITING · Phase 2
-
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
RECRUITING · Phase 2
-
Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia